CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: A pilot study on in vivo CYP3A activity

European Journal of Clinical Pharmacology

Volumn 66, Issue 4, 2010, Pages 383-386

  Gréen, Henrik ^a   Skoglund, Karin ^a   Rommel, Franz ^b   Mirghani, Rajaa A ^c,d   Lotfi, Kourosh ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d KING FAHAD MEDICAL CITY   (Saudi Arabia)

Author keywords

CGP74588; Chronic myeloid leukemia; Complete molecular response; CYP3A4; CYP3A5; Imatinib

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; BCR ABL PROTEIN; CYTOCHROME P450 3A; IMATINIB; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LEUKOPENIA; LIVER TOXICITY; MALE; PHENOTYPE; PILOT STUDY; PRIORITY JOURNAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; CHEMICALLY INDUCED DISORDER; GENETICS; METABOLISM; REMISSION;

CYTOCHROME P-450 CYP3A; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PILOT PROJECTS; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION;

EID: 77953934202     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0772-y     Document Type: Article

References (20)

1. Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M et al (2004) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44:158-162
2. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942
3. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P et al (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503-1512
4. Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44:879-894
5. Marull M, Rochat B (2006) Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple- quadrupole and linear ion trap mass spectrometers. J Mass Spectrom 41:390-404
6. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronicmyeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022-4028
7. le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G et al (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53:313-323
8. Rochat B (2005) Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinibmetabolism. Clin Pharmacokinet 44:349-366
9. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18:73-79
10. Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Berti
11. Mirghani RA, Ericsson O, Cook J, Yu P, Gustafsson LL (2001) Simultaneous determination of quinine and four metabolites in plasma and urine by high-performance liquid chromatogr (Pubitemid 38392356)
12. Green H, Lotfi K, Zackrisson AL, Peterson C (2003) Spontaneous reversal of p-glycoprotein expression in multidrug resistant cell lines. Pharmacol Toxicol 93:297-304
13. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858
14. Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ (2004) Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 76:323-329
15. Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U et al (2004) Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 53:102-106
16. Dutreix C, Peng B, Mehring G, Hayes M, Capdeville R, Pokorny R et al (2004) Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 54:290-294
17. Petain A, Kattygnarath D, Azard J, Chatelut E, Delbaldo C, Geoerger B et al (2008) Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 14:7102-7109
18. Gambacorti-Passerini C, ZucchettiM, Russo D, Frapolli R, VergaM, Bungaro S et al (2003) Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 9:625-632
19. Quintas-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D et al (2009) Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 113:6315-6321
20. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al (2006) Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108:1478-1484 (Pubitemid 39304422)